Active Ingredient(s): Lumateperone
FDA Approved: * December 20, 2019
Category: Antipsychotic

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Caplyta Overview

Lumateperone (INN; brand name Caplyta kp-LY-t, developmental codes ITI-007 and ITI-722) is a butyrophenone atypical antipsychotic developed by Intra-Cellular Therapies, licensed from Bristol-Myers Squibb, for the treatment of schizophrenia,[2] and currently in development for bipolar depression and other neurological indications.[3] The most common side effects include sleepiness and dry mouth.[4] Contents 1 Medical uses 1.1 Schizophrenia 2...

Read more Caplyta Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Caplyta Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Capsule: 42mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Caplyta: (1 result)

Sorted by National Drug Code
  • 72060-142 Caplyta 42 mg Oral Capsule by Intra-cellular Therapies, Inc

Other drugs which contain Lumateperone or a similar ingredient: (1 result)

Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 4 August 2021.

We are committed to your privacy.

Copyright © 2005-2021 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA